Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
medical device investing Knight Therapeutics Announces Health Canada Approval for JORNAY PM to Treat Attention-Deficit Hyperactivity Disorder
medical device investing Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
medical device investing Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
medical device investing Knight Therapeutics Inc. announces voting results from the Annual General Meeting
Group Eleven Drills 25.6m of 9.2% Zn+Pb and 28 g/t Ag and Extends Deeper Cu-Ag Zone with 17.4m of 35 g/t Ag and 0.31% Cu at Ballywire Discovery
